{"id":959953,"date":"2026-05-07T16:08:41","date_gmt":"2026-05-07T20:08:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/"},"modified":"2026-05-07T16:08:41","modified_gmt":"2026-05-07T20:08:41","slug":"an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/","title":{"rendered":"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum"},"content":{"rendered":"

<\/p>\n

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum<\/b><\/p>\n

MENLO PARK, Calif.–(BUSINESS WIRE<\/a>)–
\nAN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1×1 meetings.<\/p>\n

\nA webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com<\/a>. An archived replay will be available for at least 30 days following the presentation.<\/p>\n

About AN2 Therapeutics, Inc.<\/b><\/p>\n

\nAN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260507382103\/en\/<\/a><\/span><\/p>\n

COMPANY CONTACT:
\n<\/b>
Lucy O. Day
\n
Chief Financial Officer
\n
l.day@an2therapeutics.com<\/a><\/p>\n

INVESTOR AND MEDIA CONTACT:
\n<\/b>
Anne Bowdidge
\n
ir@an2therapeutics.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Oncology Health Infectious Diseases Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum MENLO PARK, Calif.–(BUSINESS WIRE)– AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1×1 meetings. A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused … <\/p>\n

Continue reading “AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-959953","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum MENLO PARK, Calif.–(BUSINESS WIRE)– AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1×1 meetings. A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused … Continue reading "AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T20:08:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260507382103r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum\",\"datePublished\":\"2026-05-07T20:08:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/\"},\"wordCount\":257,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260507382103r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/\",\"name\":\"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260507382103r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-05-07T20:08:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260507382103r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260507382103r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/","og_locale":"en_US","og_type":"article","og_title":"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - Market Newsdesk","og_description":"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum MENLO PARK, Calif.–(BUSINESS WIRE)– AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1×1 meetings. A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused … Continue reading \"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-07T20:08:41+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260507382103r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum","datePublished":"2026-05-07T20:08:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/"},"wordCount":257,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260507382103r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/","name":"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260507382103r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-05-07T20:08:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260507382103r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260507382103r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=959953"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959953\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=959953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=959953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=959953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}